Effects of down-regulating PD-L1 expression on gefitinib-resistant non-small cell lung cancer cells
返回论文页
|更新时间:2022-06-24
|
Effects of down-regulating PD-L1 expression on gefitinib-resistant non-small cell lung cancer cells
Journal of Chongqing Medical UniversityVol. 47, Issue 2, Pages: 156-161(2022)
作者机构:
1. 新乡医学院第一附属医院肿瘤科,卫辉,453100
2. 新乡医学院基础医学院病理科,新乡,453003
作者简介:
基金信息:
DOI:
CLC:
Published:2022,
扫 描 看 全 文
Ji Yinghua, Yang Xiaoyu, Meng Xiangli, et al. Effects of down-regulating PD-L1 expression on gefitinib-resistant non-small cell lung cancer cells. [J]. Journal of Chongqing Medical University 47(2):156-161(2022)
DOI:
Ji Yinghua, Yang Xiaoyu, Meng Xiangli, et al. Effects of down-regulating PD-L1 expression on gefitinib-resistant non-small cell lung cancer cells. [J]. Journal of Chongqing Medical University 47(2):156-161(2022)DOI:
Effects of down-regulating PD-L1 expression on gefitinib-resistant non-small cell lung cancer cells
目的:研究下调程序性细胞死亡配体1(programmed cell death ligand 1,PD-L1)表达对吉非替尼耐药性(gefitinib-resistant,GR)非小细胞肺癌细胞的作用及机制。方法:通过RT-qPCR和Western blot检测各非小细胞肺癌细胞程序性细胞死亡1(programmed cell death 1,PD1)和PD-L1 mRNA和其蛋白表达水平;获得GR细胞H1703/GR,CCK-8检测细胞活性,Western blot检测PD1和PD-L1 蛋白表达;转染sh-PD-L1进入H1703/GR细胞,CCK-8检测细胞活性,流式细胞术检测细胞凋亡,Western blot检测PI3K/Akt/mTOR通路相关蛋白的表达;加入PI3K/Akt/mTOR通路激活剂IGF-1,CCK-8检测细胞活性,流式细胞术检测细胞凋亡。结果:与人永生化肺上皮细胞株16HBE相比,非小细胞肺癌细胞株GLC82、A549、PC9、SK-MES-1、H1703、L78、H460、H661中PD1和PD-L1 mRNA及蛋白表达均上调(P<0.05、P<0.01),选取H1703细胞进行后续实验;与H1703细胞相比,H1703/GR细胞活性升高,PD1和PD-L1蛋白表达均上调(P<0.01);与GR组相比,GR+sh-PD-L1组H1703/GR细胞活性明显降低,细胞凋亡率明显增加,p-Akt/Akt和p-mTOR/mTOR蛋白表达明显下调(P<0.01);与GR+sh-PD-L1组相比,GR+sh-PD-L1+IGF-1组H1703/GR细胞活性明显升高,细胞凋亡率明显减少(P<0.01)。结论:下调PD-L1 表达可能通过抑制PI3K/Akt/mTOR通路激活,增强非小细胞肺癌对吉非替尼的敏感性。
Abstract
Objective:To investigate the effect and mechanism of down-regulation of programmed cell death ligand 1(PD-L1) expression on gefitinib-resistant(GR) non-small cell lung cancer cells. Methods:The expression levels of programmed cell death 1 (PD1) and PD-L1 mRNA and protein in non-small cell lung cancer cells were detected by RT-qPCR and Western blot. GR cells H1703/GR were obtained. Cell activity was detected by CCK-8. Western blot was used to detect PD1 and PD-L1 protein expression. Sh-PD-L1 was transfected into H1703/GR cells,cell activity was detected by CCK-8,apoptosis was detected by flow cytometry,and PI3K/Akt/mTOR pathway-related protein expression was detected by Western blot. PI3K/Akt/mTOR pathway activator IGF-1 was added,cell activity was detected by CCK-8 and apoptosis was detected by flow cytometry. Results:Compared with human immortalized lung epithelial cell line 16HBE,the expressions of PD1 and PD-L1 mRNA and protein in non-small cell lung cancer cell lines GLC82,A549,PC9,SK-MES-1,H1703,L78,H460,and H661 were all up-regulated(P<0.05,P<0.01),and H1703 cells were selected for subsequent experiments. Compared with H1703 cells,H1703/GR cells increased activity,and both PD1 and PD-L1 protein expressions were up-regulated(P<0.01). Compared with GR group,GR+sh-PD-L1 group significantly reduced H1703/GR cell viability,increased apoptotic rate and decreased p-Akt/Akt and p-mTOR/mTOR protein expression(P<0.01). Compared with GR+sh-PD-L1 group,the activity of H1703/GR cells in GR+sh-PD-L1+IGF-1 group was significantly increased and the apoptosis rate was significantly reduced(P<0.01). Conclusion:Down-regulating PD-L1 expression enhances the sensitivity of non-small cell lung cancer to gefitinib by inhibiting activation of the PI3K/Akt/mTOR pathway.
关键词
非小细胞肺癌吉非替尼PD1PD-L1
Keywords
non-small cell lung cancergefitinibprogrammed cell death 1programmed cell death ligand 1
Efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with docetaxel monotherapy in previously treated advanced non-small-cell lung cancer:a Meta-analysis
Clinical observation of gefitinib combined with Endostar in the first-line treatment of EGFR mutation positive advanced lung adenocarcinoma
Advances in immunotherapy in EGFR-mutated non-small cell lung cancer
Long non-coding RNA MIR155HG promotes proliferation,migration and invasion of A549 human lung cancer cells
Effect of connexin 43 on the primary resistance to gefitinib in non-small-cell lung cancer cells
Related Author
Yang Yingqing
Jiang Depeng
Jiang Youfan
Yan Qin
Wei Kunchen
Wu Junfeng
Tang Hao
Sun Bailin
Related Institution
Department of Respiratory Diseases,the Second Affiliated Hospital,Chongqing Medical University
Department of Oncology, Chengdu Fifth Peoples Hospital
Department of Respiratory and Critical Care Medicine,Shanghai Changzheng Hospital
Beijing Garrison District Haidian 40th Separation Cadre Retreat
Department of Internal Medicine,Chongqing Jianshe Hospital